Document Detail


Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.
MedLine Citation:
PMID:  18066677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lipid abnormalities, and especially hypertriglyceridaemia, are a prominent feature of peritoneal dialysis (PD) patients. The results from several studies have shown that statins are effective and safe lipid-lowering agents in these individuals. Besides lipid lowering, current evidence suggests that these agents exert multiple beneficial effects on PD patients. Statins may maintain residual kidney function by altering the response of the kidneys to dyslipidaemia and, thus, slow the progression of renal failure in PD patients. Also, statins may reduce the incidence of cardiovascular events, as well as morbidity and mortality rates in this high-risk group. However, despite the multiple beneficial effects, PD patients receive suboptimal statin treatment. Apart from the German Dialysis and Diabetes (4D) study, no other prospective, randomised controlled trial has investigated the effects of statin treatment on dialysis patients. The results of large-scale, multi-centre randomised controlled studies (such as AURORA and SHARP) are expected to define the role of statin therapy in this high-risk population.
Authors:
Kosmas I Paraskevas
Related Documents :
22072247 - Drug-induced acute pancreatitis in a cohort of 328 patients. a single-centre experience...
21576007 - Oxidative stress in patients with clinically mild encephalitis/encephalopathy with a re...
21681687 - Spontaneous in vitro il-6 production in various intestinal segments in patients with in...
21632127 - Role of cardiovascular risk factors (crf) in the patients with mild cognitive impairmen...
12114367 - Prognostic factors of non-hiv immunocompromised patients with pulmonary infiltrates.
11265797 - Radiofrequency ablation: a cure for tachyarrhythmias.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-12-08
Journal Detail:
Title:  International urology and nephrology     Volume:  40     ISSN:  0301-1623     ISO Abbreviation:  Int Urol Nephrol     Publication Date:  2008  
Date Detail:
Created Date:  2008-03-18     Completed Date:  2008-09-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0262521     Medline TA:  Int Urol Nephrol     Country:  Hungary    
Other Details:
Languages:  eng     Pagination:  165-70     Citation Subset:  IM    
Affiliation:
Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK. paraskevask@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use
C-Reactive Protein / analysis
Chronic Disease
Heptanoic Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Hypertriglyceridemia / blood,  drug therapy,  mortality
Kidney Diseases / therapy*
Lipids / blood*
Peritoneal Dialysis*
Pyrroles / therapeutic use
Risk Assessment
Risk Factors
Survival Rate
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Pyrroles; 110862-48-1/atorvastatin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential for reducing air pollution from oil refineries.
Next Document:  Diversity of basidiomycetous phylloplane yeasts belonging to the genus Dioszegia (Tremellales) and d...